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Pharmacophore modeling, molecular docking and in silico ADME prediction of a series of 
quinazoline based EGFR inhibitors [1,2,3] was performed using Schrodinger software. The study 
was performed inorder to identify the binding pattern and drug likeliness nature of these EGFR 
inhibitors. A five point pharmacophore model (AAARR.7) was generated for these compounds. The 
model came out to be statistically significant with a good correlation coefficient (R
2
) of 0.9433, 
which was considerably towards higher side, a cross validation coefficient (Q
2
) of 0.8493 and F 
value of 97.10 at 6 component PLS factor. Results of external validation were also indicative of high 
predictive power (R
2
 =0.86). The model also passed Tropsha’s test for predictive ability and Y-
randomization test. The Domain of Applicability (APD) of the model was also successfully defined 
to ascertain whether the given prediction can be considered reliable or not. Further, to determine the 
effectiveness of docking protocol, co-crystallized ligand was extracted from the ligand binding 
domain of the protein and was re-docked into the same position. The conformer obtained on re-
docking and the cocrystallized ligand were superimposed. Root mean square deviation (RMSD) 
between the two was found to be 1.005 A°, justifying the efficacy of performed docking. Outcomes 
of this work provide an insight for the development of novel potential EGFR inhibitors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Qin X. et al. Bioorganic & Medicinal Chemistry, 2016, 24: 2871-2881. 
2. Qin X. et al. Bioorganic & Medicinal Chemistry Letters, 2016, 26: 1571-1575. 
3. Qin X. et al. Anticancer Agents in Medicinal Chemistry, 2015, 15: 267-273. 
The authors would like to acknowledge Jamia Hamdard, New Delhi, India-110062. 
